• Corpus ID: 2684606

MCF-7: the first hormone-responsive breast cancer cell line.

  title={MCF-7: the first hormone-responsive breast cancer cell line.},
  author={Anait S. Levenson and V Craig Jordan},
  journal={Cancer research},
  volume={57 15},
On Thursday,January2, 1997, Dr. HerbertSoule, the scientist who developed the MCF-7 breast cancer cell line, died. At the time, we were in the process of writingthis tributeto markthe 25th anniversary of Dr. Soule's remarkableaccomplishment.The cells, derived from a breast cancer patient in the Detroit area and developed at the Michigan CancerFoundation,Detroit,became a standardmodel in hundredsof laboratories around the world. In retrospect, the story of the diverse uses of these cells is… 

Figures from this paper

The Story of MCF-7 Breast Cancer Cell Line: 40 years of Experience in Research.

A broad description of the MCF-7 cell line is provided, including the molecular profile, proliferation, migration, invasion, spheroid formation, its involvement in angiogenesis and lymphangiogenic and its interaction with the mesenchymal stem cells.

MCF-7 cells--changing the course of breast cancer research and care for 45 years.

The past, present, and future of research using MCF-7 breast cancer cells are reviewed.

Apoptosis, Chemoresistance, and Breast Cancer: Insights From the MCF-7 Cell Model System

This review summarizes important studies addressing tumor necrosis factor-α as a prototypical apoptosis-inducing cytokine in MCF-7 cells and proposes ceramide metabolism as a novel target for chemosensitivity, perhaps combined with selective inhibitors of Bcl-2 or PI3K/Akt/nuclear factor-κB.

Models and mechanisms of acquired antihormone resistance in breast cancer: significant clinical progress despite limitations

This review focuses on the critical role of the few ER-positive cell lines (MCF-7, T47D, BT474, ZR-75-1) that continue to advance the understanding of the estrogen-regulated biology of breast cancer.

Development of a Breast Cancer Stem Cell Model and the Inhibitory Regulation of Small Molecule Phytochemicals on Various Stages of Human Breast Cancer Cells

The preclinical results implicate I3C as a novel anti-cancer agent that can selectively target cancer stem cells especially given that I3D also increases MDM2-nucleostemin interactions and can reduce tumors volumes in vivo.

Estrogen/Estrogen Antagonist Regulation of the Cell Cycle in Breast Cancer Cells

Tamoxifen, the antiestrogen most commonly employed in the treatment of hormone sensitive breast cancer, significantly decreases the rates of both disease recurrence and death and is limited by the frequent development of cellular resistance.

Morphological Evidence for a Subpopulation Selection Effect by Estrogen and Antiestrogen Treatments in the Heterogeneous MCF-7 Cell Line

The combination of cell count, cytomorphology, and cell organisation revealed the magnitude of the potential of structuration of hormones or antihormones on in vitro growing cells.

Modification of oestrogen signalling during the acquisition of hormone resistance in breast cancer cells

Investigation of changes in endocrine response and ER transcription activation during the acquisition of endocrine resistance in breast cancer cell lines suggests ERa functionality in these cell lines.

Molecular Modulation of Estrogen-Induced Apoptosis in Long-Term Estrogen-Deprived Breast Cancer Cells

The data suggest that MCF-7:2A c ells employ stronger antioxidant defense mechanisms than do MCF:5C cells, and that oxidati ve stress is ultimately required for MCF7:1A cells to die in response to E 2 treatment, as well as that increased insulin-like growth factor receptor beta confers a mechanism of growth and anti-apoptotic advantage in MCFs.

The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer.

  • V. Jordan
  • Biology, Medicine
    Endocrine-related cancer
  • 2015
Evidence that the molecular events associated with estrogen-induced apoptosis can be orchestrated in the laboratory in estrogen-deprived breast cancers now supports the clinical findings regarding the treatment of metastatic breast cancer following estrogen deprivation, decreases in mortality following long-term antihormonal adjuvant therapy, and the results of treatment with ERT and ERT plus progestin in the Women's Health Initiative.



Clonal variation of MCF-7 breast cancer cells in vitro and in athymic nude mice.

The allozyme phenotype at seven polymorphic human loci (allozyme genetic signature) demonstrated that the MCF-7 line and its derivatives were derived from the same individual and were distinct from the signatures of HeLa and a variety of other human breast cancer lines.

Characterization of the estrogen receptor in two antiestrogen-resistant cell lines, LY2 and T47D.

The ER appears to be normal in two independently isolated breast cancer cell lines whose growth is resistant to the inhibitory effect of antiestrogens.

MCF10AT: a model for the evolution of cancer from proliferative breast disease.

A human cell line (MCF10A) originated from spontaneous immortalization of breast epithelial cells obtained from a patient with fibrocystic disease. MCF10A cells do not survive in vivo in

Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro.

It is demonstrated that a suppression immune function can facilitate the growth of MCF-7TAM in athymic animals and additional components of the host environment contribute to TAM-stimulated growth in vivo.

Selection and characterization of a breast cancer cell line resistant to the antiestrogen LY 117018.

The phenotypic stability of the antiestrogen resistance in LY2 cells coupled with the cross-resistance theAntiestrogens of widely different structures make this cell line an ideal model system for the study of hormone resistance in human breast cancer.

Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture.

Antiestrogens and estrogens have prominent effects on the cell cycle kinetics of endocrine-dependent human breast cancer cells and have important implications for the design of rational clinical trials of combined chemoendocrine therapy.

Growth of a human mammary tumour cell line in a serum-free medium

It is reported that MCF-7 cells may be grown, without a lag or adaptation phase, in a serum-free medium supplemented with physiological levels of insulin, transferrin, epidermal growth factor, prostaglandin F2α (PGF2α) and cold-insoluble globulin (CIg), which will support a growth rate identical to that of cells inmedium supplemented with an optimal concentration of fetal calf serum.

Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo.

Sublines isolated by in vivo but not in vitro selection are more invasive than the parental cells both in vivo and across an artificial basement membrane in vitro, suggesting as yet unknown tumor-host interactions may be important in the development of an invasive phenotype.

Use of two MCF-7 cell variants to evaluate the growth regulatory potential of estrogen-induced products.

Results confirm that the pS2 gene and Mr 52,000 protein are estrogen-regulated elements, but the lack of correlation between their activities and variant cell growth suggests that they are not major autocrine growth-stimulatory agents.